The stock of Silk Road Medical Inc (SILK) has seen a -0.11% decrease in the past week, with a 0.15% gain in the past month, and a 22.91% flourish in the past quarter. The volatility ratio for the week is 0.32%, and the volatility levels for the past 30 days are at 0.38% for SILK. The simple moving average for the past 20 days is 0.10% for SILK’s stock, with a 49.37% simple moving average for the past 200 days.
Is It Worth Investing in Silk Road Medical Inc (NASDAQ: SILK) Right Now?
SILK has 36-month beta value of 1.53. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SILK is 38.05M, and currently, short sellers hold a 6.75% ratio of that float. The average trading volume of SILK on August 21, 2024 was 1.84M shares.
SILK) stock’s latest price update
Silk Road Medical Inc (NASDAQ: SILK) has seen a rise in its stock price by 0.15 in relation to its previous close of 27.05. However, the company has experienced a -0.11% decline in its stock price over the last five trading sessions. prnewswire.com reported 2024-08-20 that NEW YORK, Aug. 20, 2024 /PRNewswire/ — Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Silk Road Medical, Inc. (Nasdaq: SILK ), relating to its proposed merger with Boston Scientific Corporation and Seminole Merger Sub.
Analysts’ Opinion of SILK
Argus, on the other hand, stated in their research note that they expect to see SILK reach a price target of $24. The rating they have provided for SILK stocks is “Buy” according to the report published on March 07th, 2024.
Stifel gave a rating of “Buy” to SILK, setting the target price at $20 in the report published on January 19th of the current year.
SILK Trading at 2.60% from the 50-Day Moving Average
After a stumble in the market that brought SILK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -0.51% of loss for the given period.
Volatility was left at 0.38%, however, over the last 30 days, the volatility rate increased by 0.32%, as shares surge +0.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +28.63% upper at present.
During the last 5 trading sessions, SILK fell by -0.11%, which changed the moving average for the period of 200-days by +227.17% in comparison to the 20-day moving average, which settled at $27.06. In addition, Silk Road Medical Inc saw 120.78% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SILK starting from Klemz Kevin M, who proposed sale 2,268 shares at the price of $27.10 back on Aug 19 ’24. After this action, Klemz Kevin M now owns shares of Silk Road Medical Inc, valued at $61,469 using the latest closing price.
Davis Andrew S., the Chief Commercial Officer of Silk Road Medical Inc, sale 66 shares at $27.00 during a trade that took place back on Jul 03 ’24, which means that Davis Andrew S. is holding 289,707 shares at $1,782 based on the most recent closing price.
Stock Fundamentals for SILK
Current profitability levels for the company are sitting at:
- -0.31 for the present operating margin
- 0.74 for the gross margin
The net margin for Silk Road Medical Inc stands at -0.3. The total capital return value is set at -0.25. Equity return is now at value -36.45, with -21.21 for asset returns.
Based on Silk Road Medical Inc (SILK), the company’s capital structure generated 0.33 points at debt to capital in total, while cash flow to debt ratio is standing at -0.44. The debt to equity ratio resting at 0.5. The interest coverage ratio of the stock is -17.38.
Currently, EBITDA for the company is -55.48 million with net debt to EBITDA at -1.15. When we switch over and look at the enterprise to sales, we see a ratio of 6.08. The receivables turnover for the company is 7.29for trailing twelve months and the total asset turnover is 0.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.63.
Conclusion
To put it simply, Silk Road Medical Inc (SILK) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
